InterventionsHumans

Real-World Risk Reduction of Cardiometabolic Comorbidities and Improvement of Biomarkers among Patients with Overweight or Obesity Treated with Semaglutide 2.4 mg

AHA Scientific Sessions 2025 Abstract

The paper

Ruseva A, Bassan M, Du E et al.

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4368652

doi.org/10.1161/circ.152.suppl_3.4368652

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Low-carb telemedicine links to fewer cardiovascular events
Cardiology and Therapy · 4 Oct 2026